YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma


Por: Chamorro-Jorganes, A, Profitós-Pelejà, N, Recasens-Zorzo, C, Valero, J, Reyes-Garau, D, Magnano, L, Butler, R, Postigo, A, Pérez-Galán, P, Ribeiro, ML and Roué, G

Publicada: 1 mar 2025 Ahead of Print: 1 feb 2025
Resumen:
A significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) cases harbor a gain-of-function, heterozygous somatic mutation of the methyltransferase gene EZH2. While this factor is known to cooperate with the proto-oncogene MYC during malignant B cell development, the effect of interfering with both factors remains underexplored. Here we undertook the simultaneous evaluation of two epigenetic drugs targeting EZH2 methyltransferase activity and BRD4-mediated control of MYC transcription, CPI169 and CPI203, using preclinical models of DLBCL and FL with distinct EZH2 mutational status. We observed a specific and synergistic antiproliferative effect of these compounds in EZH2-mutated cells and mouse xenograft models, that was related to the abrogation of MYC transcriptional program and to tumor cell proliferation blockade at the G1 cell cycle phase. Gene expression profile, exploratory data analysis, and siRNA screening identified the PI3K/ AKT-regulated gene and mitosis regulator, YPEL2, as a crucial factor involved in the efficacy of MYC/EZH2 dual targeting both in vitro and in vivo. Altogether, our results provide first pre-clinical evidence that simultaneous targeting of MYC and EZH2 is a safe and efficient approach that can be monitored by specific biomarkers, in aggressive lymphoid tumors of germinal center origin.

Filiaciones:
Chamorro-Jorganes, A:
 Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain

:
 Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain

 Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain

Recasens-Zorzo, C:
 Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain

Valero, J:
 Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain

 Ctr Invest Biomed Red Oncol CIBERONC, Madrid, Spain

Reyes-Garau, D:
 Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain

Magnano, L:
 Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain

Butler, R:
 Butler Sci, Barcelona, Spain

Postigo, A:
 ICREA, Grp Gene Regulat Stem Cells & Cell Plast, IDIBAPS, Barcelona, Spain

Pérez-Galán, P:
 Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain

 Ctr Invest Biomed Red Oncol CIBERONC, Madrid, Spain

Ribeiro, ML:
 Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain

 Sao Francisco Univ, Med Sch, Lab Immunopharmacol & Mol Biol, Braganca Paulista, SP, Brazil

:
 Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain
ISSN: 15228002





Neoplasia
Editorial
Elsevier BV, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Países Bajos
Tipo de documento: Article
Volumen: 61 Número:
Páginas: 101131-101131
WOS Id: 001423383500001
ID de PubMed: 39914169
imagen Green Submitted, gold

MÉTRICAS